about
A plasma kallikrein-dependent plasminogen cascade required for adipocyte differentiationTissue plasminogen activator is a potent activator of PDGF-CCImpact of venous thromboembolism and anticoagulation on cancer and cancer survivalCancer and venous thromboembolic disease: from molecular mechanisms to clinical management.Proteolysis in human breast cancer.Oxygen as a regulator of cellular phenotypes in pregnancy and cancer.Overexpression of plasminogen activator inhibitor 2 in human melanoma cells inhibits spontaneous metastasis in scid/scid micePlasminogen activation/plasmin in rheumatoid arthritis: matrix degradation and more.Coordinated induction of extracellular proteolysis systems during experimental autoimmune encephalomyelitis in mice.Activation of the urokinase plasminogen activator/urokinase plasminogen activator receptor system and redistribution of E-cadherin are associated with hepatocyte growth factor-induced motility of pancreas tumor cells overexpressing Met.Urokinase-type plasminogen activator-deficient mice are predisposed to staphylococcal botryomycosis, pleuritis, and effacement of lymphoid follicles.Detection of mRNAs for urokinase-type plasminogen activator, its receptor, and type 1 inhibitor in giant cell tumors of bone with in situ hybridization.Oestradiol regulation of the components of the plasminogen-plasmin system in MDA-MB-231 human breast cancer cells stably expressing the oestrogen receptor.Upregulated expression of annexin II is a prognostic marker for patients with gastric cancer.Differential expression of human tissue factor in normal mammary epithelial cells and in carcinomasA novel uPAg-KPI fusion protein inhibits the growth and invasion of human ovarian cancer cells in vitroNatural and engineered plasmin inhibitors: applications and design strategies.The biochemistry and regulation of S100A10: a multifunctional plasminogen receptor involved in oncogenesis.Plasminogen activator inhibitor 1 may promote tumour growth through inhibition of apoptosisRole of LFB3 in cell-specific cAMP induction of the urokinase-type plasminogen activator gene.The role of annexin A2 in tumorigenesis and cancer progressionDifferent tyrosine autophosphorylation requirements in fibroblast growth factor receptor-1 mediate urokinase-type plasminogen activator induction and mitogenesis.UV irradiation induces the murine urokinase-type plasminogen activator gene via the c-Jun N-terminal kinase signaling pathway: requirement of an AP1 enhancer element.Oral administration of benzyl-isothiocyanate inhibits solid tumor growth and lung metastasis of 4T1 murine mammary carcinoma cells in BALB/c mice.Gypenosides inhibits migration and invasion of human oral cancer SAS cells through the inhibition of matrix metalloproteinase-2 -9 and urokinase-plasminogen by ERK1/2 and NF-kappa B signaling pathways.Benzyl isothiocyanate (BITC) inhibits migration and invasion of human gastric cancer AGS cells via suppressing ERK signal pathways.Angiotensin II inhibits human trophoblast invasion through AT1 receptor activation.Elimination of hydrocortisone from the medium enables tissue plasminogen activator gene expression by normal and immortalized nonmalignant human epithelial cells.A novel function of tissue factor pathway inhibitor-2 (TFPI-2) in human glioma invasion.New insights into the pathogenesis of coagulation dysfunction in acute promyelocytic leukemia.Proteolysis in colorectal cancer.Brain plasmin enhances APP alpha-cleavage and Abeta degradation and is reduced in Alzheimer's disease brains.Cell surface protease activation during RAS transformation: Critical role of the plasminogen receptor, S100A10.Altered in vitro spreading and cytoskeletal organization in human glioma cells by downregulation of urokinase receptor.Expression of plasminogen activator inhibitor type 1 by human prostate carcinoma cells inhibits primary tumor growth, tumor-associated angiogenesis, and metastasis to lung and liver in an athymic mouse model.Binding of the NG2 proteoglycan to kringle domains modulates the functional properties of angiostatin and plasmin(ogen).Proteolysis in human breast and colorectal cancer.Clinical significance of annexin II expression in human non-small cell lung cancer.Regulation of plasmin-dependent fibrin clot lysis by annexin II heterotetramer.HT-1080 fibrosarcoma cell matrix degradation and invasion are inhibited by the matrix-associated serine protease inhibitor TFPI-2/33 kDa MSPI.
P2860
Q28357136-343C45D7-0D07-4A30-83D1-2E07931DC806Q28592135-395B0A88-826E-46BD-858E-E4A05FFC8B44Q33561203-961D3309-9C62-4CEB-9797-36FB87B49009Q33763866-184D3397-BCD5-4D40-B412-34B4BB2DAC4DQ33918458-B1E0E2AB-7796-4EF9-A156-C0F2A6AAF977Q34122203-F2DAC859-4394-4358-A0CF-231EBBD3A5BEQ34832169-CA917365-2AF6-46A9-B2D9-D67F1150D661Q35083704-767B63C1-E6E1-404A-982E-A22157991F74Q35747177-EC1EC179-0748-4B84-B143-48962D974D0EQ35753150-74A9305F-D07D-4B1D-B5D9-AD5F57B57BC3Q35765344-4F631EFA-6D24-4ECE-9351-7463C06B208AQ35796413-DB3B29D9-1926-44C8-B462-227FFD1D5BA4Q36114789-C1B14D71-D3EC-44B6-8714-F033B907ABC3Q36207160-075CECF1-6F9C-41AE-BC8C-E8956A0ACB52Q36437481-701E0629-1FE5-4F97-806B-EC42D9D3633BQ36791190-6DCF6EBA-1FD6-4863-B390-56F6ABDFCDA0Q37975189-656392CC-863D-4F38-AFA5-6F01B6D3A595Q38057218-61A01FB4-207D-4F5B-94B0-E2C2A555C323Q38274802-705C9B3F-9724-44C7-88E1-456C4422F506Q38291450-62AA25F4-B2C4-4335-A0DC-78D8CF16F1C0Q38366258-555CED9B-4374-4748-BE79-41E19BD5A818Q38609582-9CDC2FDA-DBBD-443B-A4EE-A5B3AC1DB7F6Q39575499-4A49D950-06F9-4961-AE2D-5AF3E943392BQ39618107-7E61C601-AEAC-4A6E-848F-27D3DA2504CFQ39698775-288D5102-A32B-4324-BE87-81F14CA17B4AQ39700912-90442315-13E2-464F-B493-10FEA1A49AFCQ40735093-2EB51AEF-8564-4305-956E-9FD1B0E49170Q40760205-7D3C7E73-5E1A-4AA2-AA4E-FB2890EF0089Q40771328-C3DE97E7-B95A-4157-8515-606E4428B312Q40771484-71224903-34BB-486B-A826-330A877369FCQ40794766-6C827F27-2452-4E7F-8468-38A38F556B21Q40819093-CB2F4817-EE31-45B4-BCE2-81CB3E923258Q40860086-121E83A5-1512-4A74-8F0B-3529FF2BA1A4Q41071260-7893D608-3296-442C-8868-CA040C29CF60Q41263250-FC41CAA1-6425-4E0F-96CC-84EE4C46C1BAQ41746287-50FF85E7-D8F9-49A2-9400-906DD781C721Q42095382-A39F5D1C-FEDF-4389-ACB6-EF5CE0BE7C60Q43490599-52422599-33EA-421D-B486-52E8C217B0CDQ43586318-62E309E5-E96F-4FD6-B132-779378611609Q48017721-DD50C0A0-4B41-4324-A556-CC45ACE3EF66
P2860
description
1992 nî lūn-bûn
@nan
1992 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
1992 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
1992年の論文
@ja
1992年論文
@yue
1992年論文
@zh-hant
1992年論文
@zh-hk
1992年論文
@zh-mo
1992年論文
@zh-tw
1992年论文
@wuu
name
The plasminogen-plasmin system in malignancy.
@ast
The plasminogen-plasmin system in malignancy.
@en
type
label
The plasminogen-plasmin system in malignancy.
@ast
The plasminogen-plasmin system in malignancy.
@en
prefLabel
The plasminogen-plasmin system in malignancy.
@ast
The plasminogen-plasmin system in malignancy.
@en
P2860
P356
P1476
The plasminogen-plasmin system in malignancy.
@en
P2093
P2860
P2888
P304
P356
10.1007/BF01307184
P577
1992-11-01T00:00:00Z